These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 36704436)

  • 1. Efficacy and safety of FLOT regimen
    Farrokhi P; Sadeghi A; Sharifi M; Riechelmann R; Moghaddas A
    Res Pharm Sci; 2022 Dec; 17(6):621-634. PubMed ID: 36704436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome evaluation of ECF, DCF, FOLFOX, and FLOT chemotherapy regimens as perioperative treatment in elderly patients with resectable gastric cancer; A retrospective comparative study.
    Forouhari A; Moghaddas A; Darakhshandeh A
    J Res Med Sci; 2023; 28():79. PubMed ID: 38292337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
    Al-Batran SE; Homann N; Pauligk C; Goetze TO; Meiler J; Kasper S; Kopp HG; Mayer F; Haag GM; Luley K; Lindig U; Schmiegel W; Pohl M; Stoehlmacher J; Folprecht G; Probst S; Prasnikar N; Fischbach W; Mahlberg R; Trojan J; Koenigsmann M; Martens UM; Thuss-Patience P; Egger M; Block A; Heinemann V; Illerhaus G; Moehler M; Schenk M; Kullmann F; Behringer DM; Heike M; Pink D; Teschendorf C; Löhr C; Bernhard H; Schuch G; Rethwisch V; von Weikersthal LF; Hartmann JT; Kneba M; Daum S; Schulmann K; Weniger J; Belle S; Gaiser T; Oduncu FS; Güntner M; Hozaeel W; Reichart A; Jäger E; Kraus T; Mönig S; Bechstein WO; Schuler M; Schmalenberg H; Hofheinz RD;
    Lancet; 2019 May; 393(10184):1948-1957. PubMed ID: 30982686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
    Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
    Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India.
    Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
    Indian J Cancer; 2017; 54(1):47-51. PubMed ID: 29199662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Comparison of FLOT and DCF Regimens as Perioperative Treatment for Gastric Cancer.
    Uçar G; Sekmek S; Karahan İ; Ergün Y; İsak ÖA; Tunç S; Doğan M; Gürler F; Bayram D; Açıkgöz Y; Esen SA; Civelek B; Köş FT; Bal Ö; Algın E; Eren T; İmamoğlu Gİ; Urakçı Z; Yazıcı O; Özdemir N; Uncu D
    Oncology; 2024 Jul; ():1-6. PubMed ID: 39079501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of FLOT and ECF/ECX perioperative chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma.
    Zeng H; Wang C; Song LY; Jia SJ; Zeng X; Liu Q
    BMJ Open; 2022 Nov; 12(11):e060983. PubMed ID: 36375981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study.
    Moussa O; Bhogal RH; Malietzis G; Fribbens C; Starling N; Gerlinger M; Watkins D; Chau I; Rao S; Cunningham D; Allum WH; Chaudry A; Kumar S
    BJS Open; 2022 Jan; 6(1):. PubMed ID: 35195263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Does the FLOT regimen a new standard of perioperative chemotherapy for localized gastric cancer?].
    Adenis A; Samalin E; Mazard T; Portales F; Mourregot A; Ychou M
    Bull Cancer; 2020 Jan; 107(1):54-60. PubMed ID: 31980145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does docetaxel matter in metastatic gastric cancer? FOLFOX versus FLOT regimens as first-line treatment.
    Gürler F; İlhan A; Güven DC; Turhan O; Kurt İnci B; Sütçüoğlu O; Yildiz F; Arik Z; Öksüzoğlu B; Yalçin Ş; Özdemir N; Yazici O; Özet A
    Anticancer Drugs; 2022 Jan; 33(1):e477-e485. PubMed ID: 34261917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of FOLFOX and Modified DCF Chemotherapy Regimen in Patients with Advanced Gastric Adenocarcinoma.
    Pourghasemian M; Danandeh Mehr A; Molaei M; Habibzadeh A
    Asian Pac J Cancer Prev; 2020 Aug; 21(8):2337-2341. PubMed ID: 32856863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perioperative chemotherapy with 5-FU, leucovorin, oxaliplatin, and docetaxel (FLOT) for esophagogastric adenocarcinoma: ten years real-life experience from a surgical perspective.
    Sisic L; Crnovrsanin N; Nienhueser H; Jung JO; Schiefer S; Haag GM; Bruckner T; Schneider M; Müller-Stich BP; Büchler MW; Schmidt T
    Langenbecks Arch Surg; 2023 Feb; 408(1):81. PubMed ID: 36763220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of health-related quality of life with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil chemotherapy regimens as first-line systemic therapy in locally advanced inoperable or metastatic gastric or gastro-esophageal junction adenocarcinoma: A prospective study from South India.
    Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Suresh Babu MC; Rudresha AH; Lokesh KN; Rajeev LK
    South Asian J Cancer; 2018; 7(1):11-15. PubMed ID: 29600225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of docetaxel or epirubicin, combined with cisplatin and fluorouracil (DCF and ECF), regimens as first line chemotherapy for advanced gastric cancer: a retrospective analysis from Turkey.
    Teker F; Yilmaz B; Kemal Y; Kut E; Yucel I
    Asian Pac J Cancer Prev; 2014; 15(16):6727-32. PubMed ID: 25169516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).
    Dos Santos M; Lequesne J; Leconte A; Corbinais S; Parzy A; Guilloit JM; Varatharajah S; Brachet PE; Dorbeau M; Vaur D; Weiswald LB; Poulain L; Le Gallic C; Castera-Tellier M; Galais MP; Clarisse B
    BMC Cancer; 2022 May; 22(1):537. PubMed ID: 35549674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Pathological Response Rate and Complications of FOLFOX versus FLOT Regimen in Perioperative Chemotherapy for Resectable Gastric Cancer: A Prospective Study.
    Arefpour AM; Hosseini S; Basi A; Novin K; Foroughi A; Garousi M
    Asian Pac J Cancer Prev; 2023 Aug; 24(8):2791-2797. PubMed ID: 37642066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen.
    Sendur MA; Ozdemir N; Özatlı T; Yazıcı O; Aksoy S; Ekinci AS; Yazılıtaş D; Günaydın Y; Oksuzoglu B; Benekli M; Zengin N
    Med Oncol; 2014 Sep; 31(9):153. PubMed ID: 25099765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel, cisplatin, and 5-fluorouracil compared with epirubicin, cisplatin, and 5-fluorouracil regimen for advanced gastric cancer: A systematic review and meta-analysis.
    Li B; Chen L; Luo HL; Yi FM; Wei YP; Zhang WX
    World J Clin Cases; 2019 Mar; 7(5):600-615. PubMed ID: 30863759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy outcome with taxane-based versus non-taxane protocols in gastric cancer.
    Kianersi S; Salari S; Rezvani H; Araskhan MA; Shirangi A; Fathi MR; Ghorbi MD
    J Educ Health Promot; 2023; 12():205. PubMed ID: 37545995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer.
    Lorenzen S; Pauligk C; Homann N; Schmalenberg H; Jäger E; Al-Batran SE
    Br J Cancer; 2013 Feb; 108(3):519-26. PubMed ID: 23322206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.